AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX Common Stock Issued

Cash raised by issuing new shares.

AN2 Therapeutics, Inc.NASDAQ: ANTX

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued growth accelerates

Q1 FY2026 common stock issued of $37.33M rose 57329.2% year over year, ahead of the +42373.9% change in trailing-twelve-month common stock issued. Over 3 fiscal years it compounded at -88.3% a year.

Context

  • Common stock issued increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +57329.2% holds above the trailing-twelve-month pace of +42373.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.33M— QoQ
Last fiscal yearDec 2025
$113K-69.6% YoY
LTMMar 2026
$37.38M+42373.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57329.2%——
1 year-69.6%——
3-year CAGR-88.3%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
113K USD
Year-over-year change
-69.6%

Common Stock Issued vs competitors

How ANTX compares with its peers on the latest reported figures

  • ANTX's LTM Mar 2026 common stock issued of $37.38M is the 4th largest of the 6 companies compared; the peer median is $50.06M.
  • Its year-over-year change of +42373.9% is the 2nd highest of 5, against a peer median of +1580.1%.
  • Over three fiscal years its annual growth of -88.3% compares with a peer median of +67.5%.
ANTX Competitors Peer median
Common Stock Issued for ANTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$351.06M +11702097000.0%+180.1%—
IBIOiBio, Inc.LTM Jun 2026$115.09M +3133.9%+112.1%115093.0%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$50.06M +26.3%+23.0%134.7%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.38M +42373.9%-88.3%—
QTTBQ32 Bio Inc.LTM Mar 2026$10.36M ——19.3%
BOLDBoundless Bio, Inc.LTM Mar 2026$24K -100.0%+3.8%—
Peer median (excluding ANTX) $50.06M+1580.1%+67.5%134.7%

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation974K4.39M8.41M8.34M6.25M
Change in Working Capital32K3.72M5.83M(3M)164K
Accounts Receivables00000
Inventory00000
Accounts Payables417K2.5M553K641K(296K)
Other Working Capital(385K)1.22M5.28M(3.64M)460K
Other Non-Cash Items53K(615K)(2.8M)(3.28M)(1.07M)
Operating Cash Flow(20.48M)(33.46M)(53.29M)(49.26M)(29.83M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments(77.27M)(93.84M)(132.18M)(46.75M)(46.19M)
Sales of Investments27.25M72.07M88.9M101.34M74.5M
Other Investing Activities00000
Investing Cash Flow(50.02M)(21.77M)(43.28M)54.59M28.31M
Debt Repayment00000
Common Stock Issued070.37M84.53M372K113K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.2M)(11K)465K00
Financing Cash Flow78.54M70.36M84.99M372K113K
Effect of Forex Changes00000
Net Change in Cash8.03M15.12M(11.57M)5.7M(1.41M)
Free Cash Flow(20.48M)(33.46M)(53.29M)(49.26M)(29.83M)

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.